ENTITY
Gilead Sciences

Gilead Sciences (GILD US)

142
Analysis
Health CareUnited States
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
more
Refresh
27 Sep 2020 02:40

Everest Medicines IPO Initiation: Potent Medicine

Everest Medicines Everest Medicines (EVEREST HK) is a biopharmaceutical company which targets four therapeutic areas - oncology, immunology,...

Logo
404 Views
Share
02 Jun 2020 22:30

Legend Biotech IPO: Pass on Valuation

Legend Biotech (LEGN US) is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...

Logo
407 Views
Share
21 Apr 2020 11:54

Gilead to Acquire a Stake in Arcus Biosciences; Offer May Come at a Large Premium

On 16th April 2020, Bloomberg reported that Gilead Sciences is considering acquiring a significant stake in Arcus Biosciences, a cancer...

Share
05 Mar 2020 10:35

A Bottom Has Been Established; Possible Retest?

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Logo
365 Views
Share
27 Feb 2020 10:09

SELL Ascletis Pharma: Why the COVID-19 Update Does Not Make Sense

We have previously discussed the short idea of Ascletis Pharma. After a few days of retreat, the stock reacted positively today to the news related...

Logo
334 Views
Share
x